Cell Receptors pp 219-270 | Cite as

Neurotransmitter Receptors in Human Brain Diseases

  • A. Probst
  • G. Mengod
  • J. M. Palacios
Chapter
Part of the Current Topics in Pathology book series (CT PATHOLOGY, volume 83)

Abstract

Progress in our understanding of how the brain works is intimately related to the development of new techniques allowing for a more refined analysis of the brain machinery at the microscopic and molecular levels. The broad applications, in the last three decades, of biochemical techniques to the study of nervous tissues has greatly increased our understanding of the chemical makeup of the brain. Because of the high regional and cellular complexity of the brain and the low resolution of the classical biochemical approaches, histochemical methods have been devised that permit more accurate description of molecular events at a cellular or subcellular level. These new methods have taken advantage of the recent development of antibodies, radioactive markers, and molecular probes for brain antigens or nucleic acid sequences.

Keywords

Amyotrophic Lateral Sclerosis Progressive Supranuclear Palsy Progressive Supranuclear Palsy Neurotransmitter Receptor Glycine Receptor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Agid Y, Javoy-Agid F (1985) Peptides and Parkinson’s disease. Trends Neurosci 1:30–35Google Scholar
  2. Agid Y, Javoy-Agid F, Ruberg M et al. (1986) Progressive supranuclear palsy: anatomical and biochemical considerations. Adv Neurol 45:191–206Google Scholar
  3. Anderton BH, Brion JP, Flament-Durand J et al. (1988) Structure and chemistry of Alzheimer neurofibrillary tangles. In: Ulrich J (ed) Interdisciplinary topics in Gerontology 25. Karger, Basel, pp 106–118Google Scholar
  4. Appel NM, Wessendorf MW, Eide RP (1987) Thyrotropin-releasing hormone in spinal cord: coexistence with serotonin and with substance P in fibers and terminals apposing identified preganglionic-sympathetic neurons. Brain Res 415:137–143PubMedGoogle Scholar
  5. Arai H, Kobayashi K, Ichimiya Y (1984) A preliminary study of free amino acids in the postmortem temporal cortex from Alzheimer-type dementia patients. Neurobiol Aging 5:319–321PubMedGoogle Scholar
  6. Armstrong DM, Bruce G, Hersch LB, Terry RD (1986) Choline acetyltransferase immunoreactivity in neuritic plaques of Alzheimer brain. Neurosci Lett 71:229–234PubMedGoogle Scholar
  7. Aronin N, Cooper PE, Lorenz LJ, Bird ED, Sagar SM, Martin JB (1983) Somatostatin is increased in the basal ganglia in Huntington’s disease. Ann Neurol 13:519–526PubMedGoogle Scholar
  8. Aubert I, Aranjo DM, Gauthier S, Quirion R (1989) Muscarinic receptor alterations in human cognitive disorders. Abstr. of the 4th International Symposium on Subtypes of Muscarinic Receptors. Trends Pharmacol Sci (in press)Google Scholar
  9. Bancher C, Lassmann H, Budka H, Grundke-Iqbal I, Iqbal K, Wiche G, Seitelberger F (1987) Neurofibrillary tangles in Alzheimer’s disease and progressive supranuclear palsy: antigenic similarities and differences. Acta Neuropathol 74:39–46PubMedGoogle Scholar
  10. Baron JC, Mazière B, Loc’h C, Sgouropoulos P, Bonnet AM, Agid Y (1985) Progressive supranuclear palsy: loss of striatal dopamine receptors demonstrated in vivo by positron tomography. Lancet 1:1163–1164PubMedGoogle Scholar
  11. Basbaum AI (1988) Distribution of glycine receptors’ immunoreactivity in the spinal cord of the rat: cytochemical evidence for a differential glycinergic control of lamina I and V nociceptive neurons. J Comp Neurol 278:330–336PubMedGoogle Scholar
  12. Beai MF, Martin JB (1985) Reduced numbers of somatostatin receptors in the cerebral cortex in Alzheimer’s disease. Science 229:239–253Google Scholar
  13. Beai MF, Martin JB (1986) Neuropeptides and neurological disease. Ann Neurol 20:547–565Google Scholar
  14. Beai MF, Bird ED, Llanglais PJ, Martin JB (1984) Somatostatin is increased in the nucleus accum-bens in Huntington’s disease. Neurology 34:663–666Google Scholar
  15. Beai MF, Kowall NW, Mazurek F (1987) Neuropeptides in Alzheimer’s disease. In: Wurtman RJ, Corkin SH, Crowdon JH (eds) Alzheimer’s disease: advances in basic research and therapies. Center for Brain Sciences and Metabolism Charitable Trust, Cambridge, MA, pp 151–168Google Scholar
  16. Berciano J (1988) Olivopontocerebellar atrophy. In: Jankovic J, Tolosa E (eds) Parkinson’s disease and movement disorders. Urban and Schwarzenberg, Munich, pp 131–151Google Scholar
  17. Berger B, Escourolle R, Moyne MA (1976) Axones catecholaminergiques du cortex cérébral humain. Observation en histofluorescence, de biopsies cérébrales dont 2 cas de maladie d’Alzheimer. Revue Neurol (Paris) 132:183–194Google Scholar
  18. Berger B, Tassin JP, Rancurel G, Blanc G (1980) Catecholaminergic innervation of the human cerebral cortex in presenile and senile dementia. Histochemical and biochemical studies. In: Usdin E, Sourkes TL, Youdim MBH (eds) Enzymes and neurotransmitters in mental disease. Wiley, Chichester, pp 317–328Google Scholar
  19. Bernheimer H, Hornykiewicz O (1973) Brain amines in Huntington’s chorea. Adv Neurol 1:1872–1972Google Scholar
  20. Bernheimer H, Birkmayer W, Hornykiewicz O (1961) Verteilung des 5-hydroxytryptamins (Serotonin) im Gehirn des Menschen und sein Verhalten bei Patienten mit Parkinson-Syndrom. Klin Wochenschr 39:1056–1059PubMedGoogle Scholar
  21. Bird ED, Iversen LL (1982) Human brain postmortem studies of neurotransmitter and related markers. In: Lajtha A (ed) Handbook of neurochemistry, vol 2. Plenum, London, pp 225–251Google Scholar
  22. Bogerts B, Häntsch J, Herzer M (1983) A morphometric study of the dopamine-containing cell groups in the mesencephalon of normals, Parkinson patients and schizophrenics. Biol Psychiatry 18:951–969PubMedGoogle Scholar
  23. Bokobza B, Ruberg M, Scatton B, Javoy-Agid F, Agid Y (1984) 3H-spiperone binding, dopamine and HVA concentrations in Parkinson’s disease and supranuclear palsy. Eur J Pharmacol 99:167–175PubMedGoogle Scholar
  24. Bondareff W, Mountjoy CQ, Roth M (1982) Loss of neurons of origin of the adrenergic projection to cerebral cortex (nucleus locus coeruleus) in senile dementia. Neurology 32:164–168PubMedGoogle Scholar
  25. Bonner TI, Buckley NJ, Young AC, Brann MR (1987) Identification of a family of muscarinic acetylcholine receptor genes. Science 237:527–532PubMedGoogle Scholar
  26. Bonner TI, Young AC, Brann M, Buckley NJ (1988) Cloning and expression of the human and rat m5 muscarinic acetylcholine receptor genes. Neuron 1:403–410PubMedGoogle Scholar
  27. Boulter J, Evans K, Goldman D, Martin G, Treco D, Heinemann S, Patrick Y (1986) Isolation of a cDNA clone coding for possible neural nicotinic acetylcholine receptor alpha-subunit. Nature 319:368–374PubMedGoogle Scholar
  28. Bowen DM, Smith CB, White P, Davison AN (1976) Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies. Brain 99:459–496PubMedGoogle Scholar
  29. Bruyn GW (1968) Huntington’s chorea: historical, clinical and laboratory synopsis. In: Vinken P, Bruyn GW (eds) Handbook of clinical neurology, vol 6. North Holland, Amsterdam, 298–378Google Scholar
  30. Buckley NJ, Bonner TI, Brann MR (1988) Localization of a family of muscarinic receptor mRNAs in rat brain. J Neurosci 8:4646–4652PubMedGoogle Scholar
  31. Bunzow Y, van Tol HHM, Grandy DK et al. (1988) Cloning and expression of a rat D2 dopamine receptor cDNA. Nature 336:783–787PubMedGoogle Scholar
  32. Burns RS, Chiueh CC, Markey SP, Ebert MH, Jacobowitz DM, Kopin IJ (1983) A primate model for parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by Af-methyl-4-phenyl-1,1,3,6-tetrahydropyridine. Proc Natl Acad Sci USA 80:4546–4550PubMedGoogle Scholar
  33. Cash R, Raisman R, Ploska A, Agid Y (1987) Dopamine D1 receptor and cyclic AMP-dependent phosphorylation in Parkinson’s disease. J Neurochem 49:1075–1083PubMedGoogle Scholar
  34. Chan-Palay V (1988) Galanin hyperinnervates surviving neurons of the human basal nucleus of Meynert in dementia of Alzheimer’s and Parkinson’s disease: a hypothesis for the role of galanin in accentuating cholinergic dysfunction in dementia. J Comp Neurol 273:543–557PubMedGoogle Scholar
  35. Chesselet MF, Graybiel AM (1986) Striatal neurons expressing somatostatin-like immunoreactivity: evidence for a peptidergic interneuronal system in the cat. Neuroscience 17:547–572PubMedGoogle Scholar
  36. Clarke PBS, Schwartz RD, Paul SM, Pert CB, Pert A (1985) Nicotinic binding in rat brain: autoradiographic comparison of 3H-acetylcholine, 3H-nicotine and 125I-alpha-bungarotoxin. J Neurosci 5:1307–1315PubMedGoogle Scholar
  37. Collerton D (1986) Cholinergic function and intellectual decline in Alzheimer’s disease. Neuroscience 19:1–28PubMedGoogle Scholar
  38. Cortes R, Camps M, Gueye B, Probst A, Palacios JM (1989) Dopamine receptors in human brain: autoradiographic distribution of D1 and D2 sites in Parkinson syndrome of different etiology. Brain Res 483:30–38PubMedGoogle Scholar
  39. Cross AJ, Crow TJ, Ferrier IN, Johnson JA, Bloom SR, Corsellis JAN (1984) Serotonin receptor changes in dementia of the Alzheimer type. J Neurochem 43:1574–1581PubMedGoogle Scholar
  40. Cross AJ, Cross TJ, Ferrier IN, Johnson JA (1986) The selectivity of the reduction of serotonin S2 receptors in Alzheimer-type dementia. Neurobiol Aging 7:3–7PubMedGoogle Scholar
  41. Curcio CA, Kemper T (1984) Nucleus raphe dorsalis in dementia of the Alzheimer type: neurofibrillary changes and neuronal packing density. J Neuropathol Exp Neurol 43:359–368PubMedGoogle Scholar
  42. D’Amato RJ, Zweig RM, Whitehouse PJ et al. (1987) Aminergic systems in Alzheimer’s disease. Ann Neurol 22:229–236PubMedGoogle Scholar
  43. Davies P, Maloney AJF (1976) Selective loss of central cholinergic neurons in Alzheimer senile dementia. Nature 288:279–280Google Scholar
  44. Davies P, Katzman R, Terry RD (1980) Reduced somatostatin-like immunoreactivity in cerebral cortex from cases of Alzheimer disease and Alzheimer senile dementia. Nature 288:279–280PubMedGoogle Scholar
  45. Déjerine J, Thomas A (1900) L’atrophie olivo-pontocérébelleuse. Nouv Iconogr Salpêt 13:330–370Google Scholar
  46. De Souza EB, Whitehouse PJ, Kuhar MJ, Price DL, Vale WW (1986) Reciprocal changes in corticotropin-releasing factor (CRF)-like immunoreactivity and CRF receptors in cerebral cortex of Alzheimer’s disease. Nature 319:593–595PubMedGoogle Scholar
  47. Deutch AY, Holliday J, Roth RH, Chan LLY, Hawrot E (1987) Immunohistochemical localization of a neuronal nicotinic acetylcholine receptor in mammalian brain. Proc Natl Acad Sci USA 84:8697–8701PubMedGoogle Scholar
  48. Dietl MM, Probst A, Palacios JM (1986) Mapping of substance P receptors in the human brain: high densities in the substantia innominata and effect of senile dementia. Soc Neurosci Abstr 12:831Google Scholar
  49. Dietl MM, Sanchez M, Probst A, Palacios JM (1989) Substance P receptors in the human spinal cord: decrease in amyotrophic lateral sclerosis. Brain Res 483:39–49PubMedGoogle Scholar
  50. Dixon RAF, Kobilka BK, Strader DJ et al. (1986) Cloning of the gene and cDNA for mammalian beta-adrenergic receptor and homology with rhodopsin. Nature 321:75–79PubMedGoogle Scholar
  51. Dohlman HG, Caron MG, Lefkowitz RJ (1987) A family of receptors coupled to guanine nucleotide regulatory proteins. Biochemistry 26:2657–2664PubMedGoogle Scholar
  52. Dubois B, Ruberg M, Javoy-Agid F, Ploska A, Agid Y (1983) A subcortico-cortical cholinergic system is affected in Parkinson’s disease. Brain Res 288:213–218PubMedGoogle Scholar
  53. Ehringer H, Hornykiewicz O (1960) Verteilung von Noradrenalin und Dopamin (3-Hydroxy-tryptamin) im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems. Klin Wochenschr 38:1236–1239PubMedGoogle Scholar
  54. Engel WK, Siddique T, Nicoloff JT (1983) Effect on weakness and spasticity in amyotrophic lateral sclerosis of thyrotropin-releasing hormone. Lancet II:73–75Google Scholar
  55. Fargin A, Raymond JR, Lohse M J, Kobilka BK, Caron MG, Lefkowitz RJ (1988) The genomic clone G-21 which resembles a beta-adrenergic receptor sequence encodes the 5-HT 1A receptor. Nature 335:358–360PubMedGoogle Scholar
  56. Ferrante RJ, Kowall NW, Beai MF, Richardson EP, Bird ED, Martin JB (1985) Selective sparing of a class of striatal neurons in Huntington’s disease. Science 230:561–563PubMedGoogle Scholar
  57. Ferrante RJ, Beai MF, Kowall NW, Richardson EP, Martin JB (1987) Sparing of acetyl-cholinesterase-containing striatal neurons in Huntington’s disease. Brain Res 411:162–166PubMedGoogle Scholar
  58. Filloux F, Wamsley JK, Dawson TN (1987) Dopamine D2 auto- and postsynaptic receptors in the nigrostriatal pathway system of the rat brain: localization by quantitative autoradiography with 3H-sulpiride. Eur J Pharmacol 138:61–68PubMedGoogle Scholar
  59. Forno LS (1978) The locus coeruleus in Alzheimer’s disease. J Neuropathol Exp Neurol 37:614Google Scholar
  60. Frielle T, Collins S, Daniel KW, Caron MG, Lefkowitz RJ, Kobilka BK (1987) Cloning of the cDNA for the human beta-adrenergic receptors. Proc Natl Acad Sci USA 84:7920–7924PubMedGoogle Scholar
  61. Galloway PG (1988) Antigenic characteristics of neurofibrillary tangles in progressive supranuclear palsy. Neurosci Lett 91:148–153PubMedGoogle Scholar
  62. Geddes JW, Monaghan DT, Cotman CW, Lott IT, Kim RC, Chui HC (1985) Plasticity of hippocampal circuitry in Alzheimer’s disease. Science 230:1179–1181PubMedGoogle Scholar
  63. Gillberg PG, Aquilonius SM (1985) Cholinergic, opioid and glycine receptor binding sites localized in human spinal cord by in vitro autoradiography. Acta Neurol Scand 72:299–306PubMedGoogle Scholar
  64. Gillberg PG, Aquilonius SM, Eckernäs SA, Lundqvist A, Windblad B (1982) Choline acetyltransferase and substance P in the human spinal cord: changes in amyotrophic lateral sclerosis. Brain Res 250:394–397PubMedGoogle Scholar
  65. Gillberg PG, Nordberg A, Aquilonius SM (1984) Muscarinic binding sites in small homogenates and in autoradiographic sections from spinal cord of rat and man. Brain Res 300:327–333PubMedGoogle Scholar
  66. Golbe LI, Davis PH (1988) Progressive supranuclear palsy. Recent advances. In: Jankovic J, Tolosa E (eds) Parkinson’s disease and movement disorders. Urban and Schwarzenberg, Baltimore, pp 121–130Google Scholar
  67. Goldman D, Simmon D, Swanson LW, Patrick J, Heinemann S (1986) Mapping of brain areas expressing RNA homologous to two different acetylcholine receptor alpha-subunit cDNAs. Proc Natl Acad Sci USA 83:4076–4080PubMedGoogle Scholar
  68. Goldman D, Deneris E, Luyten W, Kochhar A, Patrick J, Heinemann S (1987) Members of a nicotinic acetylcholine receptor gene family are expressed in different regions of the mammalian central nervous system. Cell 48:965–973PubMedGoogle Scholar
  69. Graybiel AM, Ragsdale CW Jr (1983) Biochemical anatomy of the striatum. In: Emson PC (ed) Chemical neuroanatomy. Raven, New York, 427–504Google Scholar
  70. Greenamyre JT, Penney JB, D’Amato CJ, Hicks SP, Shoulson I (1985) Alterations in l-glutamate binding in Alzheimer’s and Huntington’s disease. Science 227:1496–1499PubMedGoogle Scholar
  71. Grenningloh G, Rienitz A, Schmitt B et al. (1987) The strychnine-binding subunit of the glycine receptor shows homology with nicotinic acetylcholine receptors. Nature 328:215–220PubMedGoogle Scholar
  72. Gross RA, Spehlmann R, Daniels JC (1978) Sleep disturbances in progressive supranuclear palsy. Electroencephalogr Clin Neurophysiol 45:16–25PubMedGoogle Scholar
  73. Guttmann M, Seeman P, Reynolds GP, Riederer P, Jellinger K, Tourtellotte WW (1986) Dopamine D2 receptor density remains constant in treated Parkinson’s disease. Ann Neurol 19:487–492Google Scholar
  74. Hedreen JC, Struble RG, Whitehouse PJ, Price DL (1984) Topography of the magnocellular basal forebrain system in human brain. J Neuropath Exp Neurol 43:1–21PubMedGoogle Scholar
  75. Hiley CR, Bird ED (1974) Decreased muscarinic receptor concentration in post-mortem brain in Huntington’s chorea. Brain Res 80:355–358PubMedGoogle Scholar
  76. Hirsch EC, Graybiel AM, Duyckaerts, Javoy-Agid F (1987) Neuronal loss in the pedunculopontine tegmental nucleus in Parkinson disease and in progressive supranuclear palsy. Proc Natl Acad Sci USA 84:5976–5980PubMedGoogle Scholar
  77. Hoffman BJ, Mezey E (1989) Distribution of serotonin 5-HT 1C receptor mRNA in adult rat brain. FEBS Lett 247:453–462PubMedGoogle Scholar
  78. Hoover DB, Hancock JC (1985) Effect of facial nerve transection on acetylcholinesterase, choline acetyltransferase and 3H-quinuclidinyl benzilate binding in rat facial nuclei. Neuroscience 15:481–487PubMedGoogle Scholar
  79. Hornykiewicz O (1978) Historical aspects and frontiers of Parkinson’s disease research. Adv Exp Med Biol 90:1–20Google Scholar
  80. Jackson IMD, Adelman LS, Munsat TL, Forte S, Lechan RM (1986) Amyotrophic lateral sclerosis: thyrotropin-releasing hormone and histidyl proline diketopiperazine in the spinal cord and cerebrospinal fluid. Neurology 36:1218–1223PubMedGoogle Scholar
  81. Javoy-Agid F, Agid Y (1980) Is the mesocortical dopaminergic system involved in Parkinson disease? Neurology 30:1326–1330PubMedGoogle Scholar
  82. Javoy-Agid F, Ruberg M, Taquet H et al. (1982) Biochemical neuropathology and Parkinson disease. Advances in neurology: proceedings of the VII International Symposium on Parkinson disease. Raven, New York, pp 189–198Google Scholar
  83. Jellinger K, Riederer P, Tomonaga M (1980) Progressive supranuclear palsy: clinicopathological and biochemical studies. J Neural Transm 16 [Suppl]:111–128Google Scholar
  84. Johansson O, Hökfelt T, Pernow B (1981) Immunocytochemical support for three putative transmitters in one neuron: coexistence of 5-hydroxytryptamine, substance P and thyrotropin releasing hormone like immunoreactivity in medullary neurons projecting to the spinal cord. Neuroscience 6:1857–1881PubMedGoogle Scholar
  85. Joyce JN, Lexow N, Bird E, Winokur A (1988) Organization of dopamine D1 and D2 receptors in human striatum: receptor autoradiographic studies in Huntington’s disease and schizophrenia. Synapse 2:546–557PubMedGoogle Scholar
  86. Julius D, MacDermott AB, Axel R, Jessel T (1988) Molecular characterization of a functional cDNA encoding the serotonin lc receptor. Science 241:558–564PubMedGoogle Scholar
  87. Kish SJ, Perry TL, Hornykiewicz O (1983) Increased GAB A receptor binding in dominantly inherited cerebellar ataxias. Brain Res 269:370–373PubMedGoogle Scholar
  88. Kish SJ, Chang LJ, Mirchandani L, Shannak K, Hornykiewicz O (1985) Progressive supranuclear palsy: relationship between extrapryamidal disturbances, dementia and brain neurotransmitter markers. Ann Neurol 18:530–536PubMedGoogle Scholar
  89. Kish SJ, Li PP, Robitaille Y, Currier R, Gilbert J, Schut L, Warsh JJ (1989) Cerebellar 3H-inositol-1,4,5-triphosphatase binding is markedly decreased in human olivopontocerebellar atrophy. Brain Res 489:373–376PubMedGoogle Scholar
  90. Kobilka BK, Maysui H, Kobilka TS et al. (1987a) Cloning, sequencing and expression of the gene coding for the human platelet alpha-2 adrenergic receptor. Science 238:650–656PubMedGoogle Scholar
  91. Kobilka BK, Dixon RAF, Frielle T et al. (1987b) cDNA for the human beta-2 adrenergic receptor: a protein with multiple membrane spanning domains and encoded by a gene whose chromosomal location is shared with that of the receptor for platelet-derived growth factor. Proc Natl Acad Sci USA 84:46–50PubMedGoogle Scholar
  92. Kobilka BK, Frielle T, Collins S et al. (1987c) An intronless gene encoding a potential member of the family of receptors coupled to guanine nucleotide regulatory proteins. Nature 329:75–79PubMedGoogle Scholar
  93. Kowall NW, Ferrante RS, Martin JB (1987) Patterns of cell loss in Huntington’s disease. Trends Neurosci 10:24–29Google Scholar
  94. Lang W, Henke H (1983) Cholinergic receptor binding and autoradiography in brains of non-neurological and senile dementia of Alzheimer type patients. Brain Res 267:271–280PubMedGoogle Scholar
  95. Lange H, Thorner G, Hopf A, Schroder KF (1976) Morphometric studies of the neuropathological changes in choreatic disease. J Neurol Sci 28:401–425PubMedGoogle Scholar
  96. Lange HW (1981) Quantitative changes of telencephalon, diencephalon and mesencephalon in Huntington’s chorea, postencephalitic and idiopathic parkinsonism. Verh Anat Ges 75:923–925Google Scholar
  97. Lechan RM, Snapper SB, Jacobson S, Jackson IMD (1984) The distribution of thyrotropin-releasing hormone (TRH) in the rhesus monkey spinal cord. Peptides 5 [Suppl 1]:186–194Google Scholar
  98. Lee T, Seeman P, Rajput A, Farley JJ, Hornykiewicz O (1978) Receptor basis for dopmainergic supersensitivity in Parkinson’s disease. Nature 278:59–61Google Scholar
  99. Lentz TL, Chester J (1977) Localization of acetylcholine receptors in central synapses. J Cell Biol 75:258–267PubMedGoogle Scholar
  100. Lindstrom JM (1986) Probing nicotinic acetylcholine receptors with monoclonal antibodies. Trends Neurosci 9:401–407Google Scholar
  101. Llorens-Cortes C, Javoy-Agid F, Taquet H, Schwarz JC (1984) Enkephalinergic markers in substantia nigra and caudate nucleus from Parkinsonian subjects. J Neurochem 43:874–877PubMedGoogle Scholar
  102. Lolait S J, O’Caroll AM, Kusano K, Müller JM, Brownstein MJ, Mahan LC (1989) Cloning and expression of a novel rat GABA A receptor. FEBS Lett 246:145–148PubMedGoogle Scholar
  103. Lübbert H, Hoffman BJ, Snutch TP et al. (1987) cDNA cloning of a serotonin 5-HT 1C receptor by electrophysiological assays of mRNA injected Xenopus oocytes. Proc Natl Acad Sci USA 84:4332–4336PubMedGoogle Scholar
  104. Lynch G, Baudry M (1984) The biochemistry of memory: a new and specific hypothesis. Science 224:1057–1063PubMedGoogle Scholar
  105. Mamalaki C, Stephenson FA, Barnard EA (1987) The GABA A benzodiazepine receptor is a heterotetramer of homologous alpha and beta subunits. EMBO J 6:561–565PubMedGoogle Scholar
  106. Manaker S, Winokur A, Rhodes H, Rainbow TC (1985) Autoradiographic localization of thyrotropin-releasing hormone (THR) receptors in human spinal cord. Neurology 35:328–332PubMedGoogle Scholar
  107. Manaker S, Caine SB, Winokur A (1988) Alterations in receptors for thyrotropin-releasing hormone, serotonin, and acetylcholine in amyotrophic lateral sclerosis. Neurology 38:1464–1474PubMedGoogle Scholar
  108. Mann DMA, Yates PO, Marcyniuk B (1987) Dopaminergic neurotransmitter systems in Alzheimer’s disease and Down’s syndrome at middle age. J Neurol Neurosurg Psychiatry 50:341–344PubMedGoogle Scholar
  109. Maragos WF, Greenamyre JT, Penney JB Jr, Young AB (1987) Glutamate dysfunction in Alzheimer’s disease. A hypothesis. Trends Neurosci 10:65–68Google Scholar
  110. Marshall PE, Landis D (1985) Huntington’s disease is accompanied by changes in the distribution of somatostatin containing neuronal processes. Brain Res 329:71–82PubMedGoogle Scholar
  111. Mash DC, Flynn DD, Potter LT (1985) Loss of M2 muscarinic receptors in the cererbral cortex in Alzheimer’s disease and experimental cholinergic denervation. Science 228:1115–1117PubMedGoogle Scholar
  112. Masu Y, Nakayama K, Tamaki H, Harada Y, Kuno M, Nakanishi S (1987) cDNA cloning of bovine substance K receptor through oocyte expression system. Nature 329:836–838PubMedGoogle Scholar
  113. McGeer PL, Eccles Sir JC, McGeer EG (1987) Molecular neurobiology of the mammalian brain. Plenum, New YorkGoogle Scholar
  114. Mengod G, Palacios JM (1990) Molecular neuropathology: the study of transmitter receptor expression in human postmortem materials by in situ hybridization and receptor autoradiography. NeuropsychopharmacologyGoogle Scholar
  115. Mengod G, Martinez-Mir MI, Vilaró MT, Palacios JM (1989) Localization of the mRNA for the dopamine D2 receptor in the rat brain by in situ hybridization histochemistry. Proc Natl Acad Sci USA 86:8560–8564PubMedGoogle Scholar
  116. Mengod G, Nguyen H, Le H, Waeber C, Lübbert H, Palacios JM (1990) The distribution and cellular localization of the serotonin 1C receptor mRNA in the rodent brain examined by in situ hybridization histochemistry. Comparison with receptor binding distribution. Neuroscience 35:577–591PubMedGoogle Scholar
  117. Mesulam MM, Mufson EJ, Levey AI, Wainer BH (1984) Atlas of cholinergic neurons in the forebrain and upper brainstem of the macaque based on monoclonal choline acetyltransferase immunohistochemistry and acetylcholinesterase histochemistry. Neuroscience 12:669–686PubMedGoogle Scholar
  118. Mitsuma T, Nogimori T, Adachi K, Mukoyama M, Ando K (1984) Concentrations of immunore-active thyrotropin-releasing hormone in spinal cord of patients with amyotrophic lateral sclerosis. Am J Med Sci 287:34–36PubMedGoogle Scholar
  119. Morley BJ, Kemp GE, Salvaterra P (1979) Alpha-bungarotoxin binding sites in the CNS. Life Sci 24:859–872PubMedGoogle Scholar
  120. Myers RH, Martin JB (1982) Huntington’s disease. Semin Neurol 2:365–372Google Scholar
  121. Nemeroff CB, Youngblood WW, Manberg PJ, Prange AJ, Kizer JS (1983) Regional brain concentration of neuropeptides in Huntington’s chorea and schizophrenia. Science 221:972–975PubMedGoogle Scholar
  122. Nghiêm HO, Cartaud J, Dubreuil C, Kordeli C, Buttin G, Changeux JP (1983) Production and characterization of a monoclonal antibody directed against the 43000-dalton VI polypeptide from torpedo marmorata electric organ. Proc Natl Acad Sci USA 80:6403–6407PubMedGoogle Scholar
  123. Oppenheimer DR (1984) Diseases of the basal ganglia, cerebellum and motor neurons. In: Adam JH, Corsellis JAN, Duchen LW (eds) Greenfields neuropathology. Edward Arnold, London, pp 700–747Google Scholar
  124. Palacios JM (1982) Autoradiographic localization of muscarinic cholinergic receptors in the hippocampus of patients with senile dementia. Brain Res 23:173–175Google Scholar
  125. Palacios JM, Kuhar MJ (1981) Neurotensin receptors are located on dopamine-containing neurons in rat midbrain. Nature 294:273–285Google Scholar
  126. Palacios JM, Niehoff DL, Kuhar MJ (1981) Receptor autoradiography with tritium-sensitive film: potential for computerized densitometry. Neurosci Lett 24:111–116Google Scholar
  127. Palacios JM, Probst A, Cortés R (1986) Mapping receptors in the human brain. Trends Neurosci 9:284–289Google Scholar
  128. Palacios JM, Cortés R, Probst A, Dietl M (1987) Autoradiographic mapping of neurotransmitter receptors in normal and pathological human brain. In: Tucek S (ed) Synaptic transmitters and receptors. Academia, Prague, pp 71–79Google Scholar
  129. Palacios JM, Camps M, Cortés R., Probst A (1988a) Mapping dopamine receptors in the human brain. J Neural Transm 27:227–235Google Scholar
  130. Palacios JM, Cortés R, Dietl M, Probst A (1988b) Receptors in human brain disease: a use for receptor autoradiography in neuropathology. J Recept Res 8:509–520PubMedGoogle Scholar
  131. Palacios JM, Mengod G, Savasta M (1989a) Mapping of receptor and transmitters expression in the human brain. In: Ottoson D (ed) Visualization of brain function. Macmillan, LondonGoogle Scholar
  132. Palacios JM, Mengod G, Vilaró MT, Wiederhold KH, Boddeke H, Alvarez FJ, Chinaglia G, Probst A (1989b) Cholinergic receptors in the rat and human brain. Microscopic visualization. Prog Brain ResGoogle Scholar
  133. Palmer AM, Wilcock GK, Esiri MM, Francis PT, Bowen DM (1987) Monoamine innervation of the frontal and temporal lobes in Alzheimer’s disease. Brain Res 401:231–238PubMedGoogle Scholar
  134. Patten BM, Croft S (1984) Spinal cord substance P in amyotrophic lateral sclerosis. In: Clifford Rose F (ed) Research progress in motor neuron disease. Pitman, Bath, pp 283–289Google Scholar
  135. Penney JB, Young AB (1982) Quantitative autoradiography of neurotransmitter receptors in Huntington’s disease. Neurology 32:1391–1395PubMedGoogle Scholar
  136. Penney JB, Young AB (1988) Huntington’s disease. In Jankovic F, Tolosa E (eds) Parkinson’s disease and movement disorders. Urban and Schwarzenberg, Baltimore, pp 167–178Google Scholar
  137. Penney JB, Young AB, Walker FO, Shoulson I (1984) Quantitative autoradiography of opiate receptors in Huntington’s disease. Neurology 34 [Suppl 1]:153Google Scholar
  138. Peralta EG, Ashkenazi A, Winslow JW, Smith DH, Ramachandran J, Capon DJ (1987) Distinct primary structures, ligand-binding properties and tissue-specific expression of four human muscarinic acetylcholine receptors. EMBO J 6:3923–3929PubMedGoogle Scholar
  139. Perret JL, Jouvet M (1980) Etude du sommeil dans la paralysie supranucléaire progressive. Electroencephalogr Clin Neurophysiol 49:323–329PubMedGoogle Scholar
  140. Perry EK, Tomlinson BE, Blessed G, Bergmann K, Gibson PH, Perry RH (1978) Correlation of cholinergic abnormalities with senile plaques and mental testscores in senile dementia. Br Med J II:1427–1429Google Scholar
  141. Perry EK, Atack JR, Perry RH et al. (1984) Intralaminar neurochemical distributions in human midtemporal cortex: comparison between Alzheimer’s disease and the normal. J Neurochem 42:1402–1410PubMedGoogle Scholar
  142. Perry TL, Kish S J, Hansen S, Currier RD (1981) Neurotransmitter amino acids in dominantly inherited cerebellar disorders. Neurology 31:237–242PubMedGoogle Scholar
  143. Perry TL, Young VW, Bergeron C, Hansen S, Jones K (1987) Amino acids, glutathione and glutathione transferase activity in the brains of patients with Alzheimer’s disease. Ann Neurol 21:331–336PubMedGoogle Scholar
  144. Petito CK, Hart MN, Porro RS, Earle KM (1973) Ultrastructural studies of olivopontocerebellar atrophy. J Neuropathol Exp Neurol 32:503–552PubMedGoogle Scholar
  145. Pfeiffer F, Simler R, Greeningloh G, Betz H (1984) Monoclonal antibodies and peptide mapping reveal structural similarities between the subunits of the glycine receptors of rat spinal cord. Proc Natl Acad Sci USA 81:7224–7227PubMedGoogle Scholar
  146. Pierot L, Desnas C, Blair J et al. (1988) Dl and D2 type dopamine receptors in patients with Parkinson’s disease and progressive supranuclear palsy. J Neurol Sci 86:291–306PubMedGoogle Scholar
  147. Pimoule C, Schoemaker H, Reynolds GP, Langer SZ (1985) 3H-SCH 23 390 labeled Dl dopamine receptors are unchanged in schizophrenia and Parkinson’s disease. Eur J Pharmacol 114:235–237PubMedGoogle Scholar
  148. Pollock NJ, Mirra SS, Binder LI, Hansen LA, Wood JG (1986) Filamentous aggregates in Pick’s disease, progressive supranuclear palsy and Alzheimer’s disease share antigenic determinants with microtubule-associated protein, tau. Lancet II:1211Google Scholar
  149. Pritchett DB, Bach AWJ, Wozny M, Talebo O, Di Toso R, Shih JC, Seeburg PH (1988) Structure and functional expression of cloned rat serotonin 5HT-2 receptor. EMBO J 7:4135–4140PubMedGoogle Scholar
  150. Pritchett DB, Sontheimer H, Shivers B, Ymer S, Kettenmann H, Schofield PR, Seeburg PH (1989) Importance of a novel GABA A receptor subunit for benzodiazepine pharmacology. Nature 38:582–585Google Scholar
  151. Probst A, Dufresne JJ (1975) Paralysie supranucléaire progressive (ou Dystonie oculo-facio-cervicale). Arch Suisses Neurol Neurochir Psychiatr 116:107–134Google Scholar
  152. Probst A, Cortés R, Palacios JM (1986) The distribution of glycine receptors in the human brain. A light microscopic autoradiographic study using 3H-strychnine. Neuroscience 17:11–35PubMedGoogle Scholar
  153. Probst A, Langui D, Lautenschlager C, Ulrich J, Brion JP, Anderton HB (1988a) Progressive supranuclear palsy: extensive neuropil threads in addition to neurofibrillary tangles. Acta Neuropathol 77:61–68PubMedGoogle Scholar
  154. Probst A, Cortés R, Ulrich J, Palacios JM (1988b) Differential modification of muscarinic cholinergic receptors in the hippocampus of patients with Alzheimer’s disease: an autoradiographic study. Brain Res 450:190–201PubMedGoogle Scholar
  155. Quirion R, Chieueh CC, Everist HD, Pert A (1985) Comparative localization of neurotensin receptors on nigrostriatal and mesolimbic dopaminergic terminals. Brain Res 327:385–389PubMedGoogle Scholar
  156. Raftery MA, Hunkapiller MW, Strader CD, Hood LE (1980) Acetylcholine receptor: complex of homologous subunits. Science 208:1454–1457PubMedGoogle Scholar
  157. Raisman R, Cash R, Ruberg M, Javoy-Agid F, Agid Y (1985) Binding of 3H-SCH 23 390 to Dl receptors in the putamen of control and parkinsonian subjects. Eur J Pharmacol 113:467–468PubMedGoogle Scholar
  158. Regan JW, Kobilka TS, Yang Feng TL, Caron MG, Lefkowitz RJ, Kobilka BK (1988) Cloning and expression of a human kidney cDNA for an alpha-2 adrenergic receptor subtype. Proc Natl Acad Sci USA 85:6301–6305PubMedGoogle Scholar
  159. Richards G, Möhler H, Schoch P, Häring P, Takacs B, Stahli C (1984) The visualization of neuronal benzodiazepine receptors in the brain by autoradiography and immunohistochemistry. J Recepì Res 4:657–669Google Scholar
  160. Richards G, Schoch P, Möhler H, Haefely W (1986a) Benzodiazepine receptors resolved. Experientia 42:121–126PubMedGoogle Scholar
  161. Richards G, Möhler H, Haefely W (1986b) Mapping benzodiazepine receptors in the CNS by radiohistochemistry and immunohistochemistry. In: Panula P, Päivärinta Svinita S (eds) Neurohistochemistry: modern methods and applications. Alan R. Liss, New York, pp 629–677Google Scholar
  162. Rinne JO, Rinne JK, Laakso K, Lönnberg P, Rinne UK (1985) Dopamine D1 receptors in the parkinsonian brain. Brain Res 359:306–310PubMedGoogle Scholar
  163. Rossor M, Iversen LL (1986) Non-cholinergic neurotransmitter abnormalities in Alzheimer’s disease. Br Med Bull 42:70–74PubMedGoogle Scholar
  164. Rotter A, Birdsall NJM, Burgen ASV, Field PM, Smolen A, Raisman G (1979) Muscarinic receptors in the central nervous system of the rat. IV. A comparison of the effects of axotomy and deafferentation on the binding of 3H-propybenzilylcholine mustard and associated synaptic changes in the hypoglossal and pontine nuclei. Brain Res Rev 1:207–224Google Scholar
  165. Rowell PP, Winkler DL (1984) Nicotinic stimulation of 3H-acetylcholine release from mouse cerebral synaptosomes. J Neurochem 43:1593–1598PubMedGoogle Scholar
  166. Ruberg M, Ploska A, Javoy-Agid F, Agid Y (1982) Muscarinic binding and choline acetyltransferase activity in Parkinsonian subjects with reference to dementia. Brain Res 232:129–139PubMedGoogle Scholar
  167. Ruberg M, Javoy-Agid F, Hirsch E et al. (1985) Dopaminergic and cholinergic lesions in progressive supranuclear palsy. Ann Neurol 18:523–529PubMedGoogle Scholar
  168. Sasaki H, Muramato O, Kanazawa I, Arai H, Kosaka K, Tizuka R (1986) Regional distribution of amino acid transmitters in postmortem brains of presenile and senile dementia of Alzheimer type. Ann Neurol 19:263–269PubMedGoogle Scholar
  169. Savasta M, Dubois A, Feuerstein C, Manier M, Scatton B (1987) Denervation supersensitivity of striatal D2-dopamine receptors is restricted to the ventro- and dorsolateral regions of the striatum. Neurosci Lett 74:180–186PubMedGoogle Scholar
  170. Savasta M, Ruberte E, Palacios JM, Mengod G (1989) The colocalization of cholecystokinin and tyrosine hydroxylase mRNAs in mesencephalic dopaminergic neurons in the rat brain examined by in situ hybridization. Neuroscience 29:363–369PubMedGoogle Scholar
  171. Scatton B, Javoy-Agid F, Rouquier L, Dubois B, Agid Y (1983) Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson’s disease. Brain Res 275:321–328PubMedGoogle Scholar
  172. Scatton B, Dubois A, Javoy-Agid F, Camus A (1984) Autoradiographic localization of muscarinic cholinergic receptors at various levels of the human spinal cord. Neurosci Lett 49:239–245PubMedGoogle Scholar
  173. Schoch P, Möhler H (1983) Purified benzodiazepine receptor retains modulation by GABA. Eur J Pharmacol 95:323–324PubMedGoogle Scholar
  174. Schoenen J, Reznik M, Delwaide PJ, Vanderhaeghen JJ (1985) Etude immunocytochimique de la distribution spinale de la substance P, des encéphalines, de la cholécystokinine et de la serotonine dans la sclérose latérale amyotrophique. CR Soc Biol (Paris) 179:528–534Google Scholar
  175. Schofield PR, Darlison MG, Fujita N et al. (1987) Sequence and functional expression of the GABA A receptor shows a ligand-gated receptor super family. Nature 328:221–227PubMedGoogle Scholar
  176. Schofield PR, Pritchett DB, Sontheimer H, Kettenmann H, Sehburg PH (1989) Sequence and expression of human GABA A receptor alpha 1 and beta 1 subunits. FEBS Lett 244:361–364PubMedGoogle Scholar
  177. Schwarz JH (1985) Molecular aspects of postsynaptic receptors. In: Kandel EM, Schwarz JH (eds) Principles of neural science, 2nd. edn Elsevier, Amsterdam, pp 159–168Google Scholar
  178. Sealock P, Barnaby EW, Froehner SC (1984) Ultrastructural localization of the Mr 43000 protein and the acetylcholine receptor in torpedo postsynaptic membranes using monoclonal antibodies. J Cell Biol 98:2239–2244PubMedGoogle Scholar
  179. Sequier JM, Richards JG, Malherbe P, Price GW, Mathews S, Möhler H (1988) Mapping of brain areas containing RNA homologous to cDNAs encoding the alpha and beta subunits of the rat GABA A alpha-aminobutyrate receptor. Proc Natl Acad Sci USA 85:7815–7819PubMedGoogle Scholar
  180. Shepherd GM (1988) Neurobiology, 2nd edn. Oxford University Press, OxfordGoogle Scholar
  181. Sigel E, Stephenson A, Mamalaki C, Barnard E A (1983) A gamma-amino-butyric acid/benzodi-azepine receptor complex of bovine cerebral cortex: purification and partial characterization. J Biol Chem 258:6965–6971PubMedGoogle Scholar
  182. Spindel ER, Wurtman RJ, Bird ED (1981) Increased TRH content in the basal ganglia in Huntington’s disease. N Engl J Med 303:1235–1236Google Scholar
  183. Steele JC (1972) Progressive supranuclear palsy. Brain 95:693–704PubMedGoogle Scholar
  184. Steele JC, Richardson JC, Olszewski J (1964) Progressive supranuclear palsy: a heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum, with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch Neurol 10:333–359PubMedGoogle Scholar
  185. Storm-Mathisen J (1976) Distribution of the components of the GABA system in neuronal tissue: cerebellum and hippocampus effects of axotomy. In: Robert E, Chase T, Tower DB (eds) GABA in nervous system function. Raven, New York, pp 149–168Google Scholar
  186. Swanson LW, Simmons DM, Whiting PJ, Lindstrom J (1987) Immunohistochemical localization of neuronal nicotinic receptors in the rodent central nervous system. J Neurosci 7:3334–3342PubMedGoogle Scholar
  187. Tanzi RE, St. George-Hyslop PH, Gusella F (1989) Molecular genetic approaches to Alzheimer’s disease. Trends Neurosci 12:152–157PubMedGoogle Scholar
  188. Tenovuo O, Rinne UK, Viljanen MK (1984) Substance P immunoreactivity in the post mortem Parkinsonian brain. Brain Res 303:113–116PubMedGoogle Scholar
  189. Troncoso JC, Cork L, Whitehouse PJ, Kuhar MJ, Price DL (1984) Canine inherited ataxia: neurotransmitter receptors in the cerebellum. Ann Neurol 16:135Google Scholar
  190. Tsiotos P, Plaitakis A, Mitsacos A, Voukelatou G, Michalodimitrakis M, Kouvelas ED (1989) Glutamate binding sites of normal and atrophic human cerebellum. Brain Res 481:87–96PubMedGoogle Scholar
  191. Uhl GR, Whitehouse PJ, Price DL, Tourtellotte WW, Kuhar M J (1984) Parkinson’s disease: depletion of substantia nigra neurotensin receptors. Brain Res 308:186–190PubMedGoogle Scholar
  192. Uhl GR, Hedreen JC, Price DL (1985) Parkinson’s disease: loss of neurons from the ventral tegmental area contralateral to therapeutic surgical lesions. Neurology 35:1215–1218PubMedGoogle Scholar
  193. Uhl GR, Hackney GO, Torchia M et al. (1986) Parkinson’s disease: nigral receptor changes support peptidergic role in nigrostriatal modulation. Ann Neurol 20:194–203PubMedGoogle Scholar
  194. Unnerstall JR, Niehoff DL, Kuhar M J, Palacios JM (1982) Quantitative receptor autoradiography using 3H ultrafilm: application to multiple benzodiazepine receptors. J Neurosci Methods 6:59–73PubMedGoogle Scholar
  195. Vilaró MT, Palacios JM, Mengod G (1990a) Localization of m5 muscarinic receptor mRNA in rat brain examined by in situ hybridization histochemistry. Neurosci. Lett. 114:154–159PubMedGoogle Scholar
  196. Vilaró MT, Wiederhold K-H, Palacios JM, Mengod G (1990b) Muscarinic cholinergic receptors in the rat caudate-putamen and olfactory tubercle belong predominantly to the m4 class: in situ and receptor autoradiography evidence. Neuroscience, in press.Google Scholar
  197. Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP (1985) Neuropatho-logical classification of Huntington’s disease. J Neuropathol Exp Neurol 44:559–577PubMedGoogle Scholar
  198. Wada K, Ballivet M, Boulter J et al. (1988) Function and expression of a new pharmacological subtype of brain nicotonic acetylcholine receptor. Science 240:330–334PubMedGoogle Scholar
  199. Waeber C, Palacios JM (1989) Serotonin-1 receptor binding sites in the human basal ganglia are decreased in Huntington’s chorea but not in Parkinson’s disease: a quantitative in vitro autoradiographic study. NeuroscienceGoogle Scholar
  200. Walker FO, Young AB, Penney JB, Dovorini-Zis K, Shoulson I (1984) Benzodiazepine and GAB A receptors in early Huntington’s disease. Neurology 34:1237–1240PubMedGoogle Scholar
  201. Wastek GJ, Stern LZ, Johnson PC, Yamamura HI (1976) Huntington’s disease: regional alteration in muscarinic cholinergic receptor binding in human brain. Life Sci 19:1033–1040PubMedGoogle Scholar
  202. Wenthold RJ, Parakkal MH, Oberdorfer MD, Altschuler RA (1988) Glycine receptor immunoreactivity in the ventral cochlear nucleus of the guinea pig. J Comp Neurol 276:423–435PubMedGoogle Scholar
  203. Whitehouse PJ (1985) Receptor autoradiography: applications in neuropathology. Trends Neurosci 8:434–437Google Scholar
  204. Whitehouse PJ, Wamsley JK, Zarbin MA, Price DL, Tourtellotte WW, Kuhar M J (1983) Amyotrophic lateral sclerosis: alterations in neurotransmitter receptors. Ann Neurol 14:8–16PubMedGoogle Scholar
  205. Whitehouse PJ, Trifiletti RR, Jones BE, Jolstein S, Price DL, Snyder SH, Kuhar MJ (1985) Neurotransmitter receptor alterations in Huntington’s disease: autoradiographic and homogenate studies with special reference to benzodiazepine receptor complex. Ann Neurol 18:202–210PubMedGoogle Scholar
  206. Whitehouse PJ, Martino AM, Marcus K, Price DL, Kellar KJ (1986a) Reductions in 3H-acetylcholine nicotinic binding sites in cortex in Alzheimer’s disease: an autoradiographic study. Neurology 36:270Google Scholar
  207. Whitehouse PJ, Muramoto O, Troncoso JC, Kanazawa I (1986b) Neurotransmitter receptors in olivopontocerebellar atrophy: an autoradiographic study. Neurology 36:193–197PubMedGoogle Scholar
  208. Whiting P, Lindstrom J (1987) Purification and characterization of a nicotinic acetylcholine receptor from rat brain. Proc Natl Acad Sci USA 84:595–599PubMedGoogle Scholar
  209. Young AB, Penney JB (1984) Neurochemical anatomy of movement disorders. Neurol Clin 2:417–433PubMedGoogle Scholar
  210. Young WS III, Kuhar MJ (1979) Autoradiographic localization of benzodiazepine receptors in brains of humans and animals. Nature 280:393–395Google Scholar
  211. Young WS III, Bonner TI, Brann MR (1986) Mesencephalic dopamine neurons regulate the expression of neuropeptide mRNAs in the rat forebrain. Proc Natl Acad Sci USA 83:9827–9831PubMedGoogle Scholar
  212. Zarbin MA, Wamsley JK, Kuhar M J (1981) Glycine receptor: light microscopic autoradiographic localization with strychnine. J Neurosci 1:532–547PubMedGoogle Scholar
  213. Zezula J, Cortés R, Probst A, Palacios JM (1988) Benzodiazepine receptor sites in the human brain: autoradiographic mapping. Neuroscience 25:771–795PubMedGoogle Scholar
  214. Zweig RM, Whitehouse PJ, Casanova MF, Walker LC, Jankel WR, Price DL (1987) Loss of pedunculopontine neurons in progressive supranuclear palsy. Ann Neurol 22:18–25PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1991

Authors and Affiliations

  • A. Probst
  • G. Mengod
  • J. M. Palacios

There are no affiliations available

Personalised recommendations